Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer
Pegilodecakin, a first-in-class drug currently in clinical trials, has shown positive safety results and may offer a potential new treatment avenue for patients with non-small cell lung cancer (NSCLC) and kidney cancer. The study, led by The University of Texas MD Anderson Cancer Center, demonstrated that the drug, in combination with two leading anti-PD-1 monoclonal antibodies, pembrolizumab and nivolumab, achieved measurable responses...
Rogers Award honors Sheryl Harris, C.N.A., for excellence in patient care
The University of Texas MD Anderson Cancer Center has awarded Sheryl Harris, C.N.A., the Julie and Ben Rogers Award for Excellence in Patient...
MD Anderson and Houston Dynamo unite to kick childhood cancer
The University of Texas MD Anderson Cancer Center goes gold for Kick Childhood Cancer Awareness Night at BBVA Stadium, Saturday, Sept. 21...
In Memory of T. Boone Pickens
The University of Texas MD Anderson Cancer Center extends deepest sympathy to family and friends of philanthropist and energy industry tycoon T. Boone Pickens. The institution mourns the loss of the
visionary leader who long served as a passionate ambassador of MD Anderson and its mission to end cancer.
“We are forever grateful to Boone for bringing his creative spirit and ingenuity to the global fight to end...
MD Anderson study confirms protein as potential cause of most common type of pancreatic cancer
Researchers at The University of Texas MD Anderson Cancer Center have confirmed a protein as an oncogene responsible for the most common and...